OV329 Evaluation in Participants with Epilepsy and PPR
Key facts
- Where
- Leiden, HollandiaSee the site
- Phase
- 2. fázis
Where in Hollandia
- Centre for Human Drug ResearchLeiden, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ovid Therapeutics Inc.
- Trial code
- EU 2026-527114-23-00
- Record updated
- 2026. november 9.
- Original description
To evaluate the pharmacodynamic effect of OV329 on the IPS-induced PPR in participants with epilepsy.Read full original descriptionShow less
Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.
To evaluate the pharmacodynamic effect of OV329 on the IPS-induced PPR in participants with epilepsy.
Inclusion: Male or female participants aged 18 to 65 years at the time of consent; Participants with a diagnosis and history of epilepsy (see exceptions in Exclusion Criteria); Participants with a reproducible IPS-induced generalized PPR of at least 4 points on a frequency assessment scale at Screening and Baseline in at least one eye condition.
Exclusion: Participants who are taking or have taken OV329 as concomitant therapy within the last 3 months, with the exception of this study; Participants with a history of non-epileptic seizures (e.g., metabolic or pseudo-seizures); Participants with a diagnosis of Classical juvenile myoclonus epilepsy characterized by exclusively or predominantly early morning myoclonic seizures, as assessed by the investigator; Participants with a known allergy to OV329 or potentially to one of its analogues.